Croatian Society of Physical and Rehabilitation Medicine, Croatian Medical Association
Abstract
Razumijevanje imunopatogeneze upalnih reumatskih bolesti još uvijek je nepotpuno. Iako je opisana uloga alarmina u različitim upalnim i autoimunim bolestima,klinička ispitivanja iz tog područja još uvijek su rijetka. U radu je prikazana literatura koja govori o značenju trinajčešća alarmina: proteina visoke pokretljivosti iz skupine 1 (HMGB1, engl. high mobility group box 1), proteina koji vežu kalcij S100A8/9 i S100A12 (S100A8/9, S100A12, engl. calcium-binding protein S100A12) i njihova topljiva receptora za krajnje produkte uznapredovale glikozilacije sRAGE (RAGE, engl. soluble receptor for advanced glycation end products) u upalnim reumatskim bolestima.Prema dosadašnjim spoznajama smatra se da HMGB1, kao medijator prirođene imunosti, u interakciji sa sRAGE sudjeluje u imunopatogenezi upalnih reumatskih bolesti te može služiti kao biomarker za određivanje aktivnosti i moguća meta u liječenju navedene skupine bolesnika.Our understanding of the imunopathogenesis of inflammatory rheumatic diseases is still incomplete. The involvement of alarmins in various inflammatory and autoimmune diseases has been documented but clinical trials on the contribution of this molecules are basically absent. In this article we summarized the literature about the significance of the three most common alarmins: high mobility group box 1 (HMGB1), calcium-binding proteins S100A8/9 and S100A12 and their soluble receptor for advanced glycation end products (sRAGE) in inflammatory rheumatic diseases. According to our previous knowledge, it is considered that HMGB1 through interactions with sRAGE contributes to imunopathogenesis of inflammatory rheumatic diseases. Furthermore, HMGB1 may serve as a biomarker for determining disease activity and a potential target of therapy in systemic inflammatory rheumatic diseases patients
